CellSource Co., Ltd. Stock

Equities

4880

JP3423580004

Healthcare Facilities & Services

Market Closed - Japan Exchange 02:00:00 2024-05-10 am EDT 5-day change 1st Jan Change
1,422 JPY -4.50% Intraday chart for CellSource Co., Ltd. -5.89% +11.18%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 4.89B 31.41M Sales 2025 * 5.65B 36.25M Capitalization 28.16B 181M
Net income 2024 * 603M 3.87M Net income 2025 * 850M 5.46M EV / Sales 2024 * 5.75 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 4.99 x
P/E ratio 2024 *
46.6 x
P/E ratio 2025 *
33.1 x
Employees 151
Yield 2024 *
0.3%
Yield 2025 *
0.38%
Free-Float 46.47%
More Fundamentals * Assessed data
Dynamic Chart
Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023. CI
MEDERI Inc. announced that it has received funding from CellSource Co., Ltd. CI
Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 24-SEP-2023. CI
Cuorips Inc. has completed an IPO in the amount of ¥3.432 billion. CI
Cellsource Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending October 31, 2023 CI
Cellsource Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending October 31, 2023 CI
CellSource Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending October 31, 2023 CI
Lumirous Sdn Bhd announced that it has received funding from CellSource Co., Ltd. CI
Cuorips Inc. announced that it has received ¥1.6 billion in funding from JIC Venture Growth Investments Co., Ltd., JAFCO Group Co., Ltd., Osaka University Venture Capital Co., Ltd., Fujifilm Corporation, CellSource Co., Ltd., Kyoto-University-Venture NVCC No.2 Investment Limited Partnership CI
CYBERDYNE Inc Forms Strategic Partnership with Cellsource Co., Ltd CI
CellSource Co., Ltd.(TSE:4880) added to S&P Global BMI Index CI
Certain Common Stock of CellSource Co., Ltd. are subject to a Lock-Up Agreement Ending on 24-APR-2020. CI
CellSource Co., Ltd. has completed an IPO in the amount of ¥1.0944 billion. CI
CellSource Co., Ltd. has filed an IPO. CI
More news
1 day-4.50%
1 week-5.89%
Current month-8.79%
1 month-1.66%
3 months+11.27%
6 months-15.76%
Current year+11.18%
More quotes
1 week
1 417.00
Extreme 1417
1 554.00
1 month
1 417.00
Extreme 1417
1 595.00
Current year
1 179.00
Extreme 1179
1 650.00
1 year
1 179.00
Extreme 1179
3 180.00
3 years
1 179.00
Extreme 1179
8 160.00
5 years
611.11
Extreme 611.1111
8 160.00
10 years
611.11
Extreme 611.1111
8 160.00
More quotes
Managers TitleAgeSince
Founder 41 15-11-29
Chief Executive Officer 66 22-01-26
Director/Board Member 61 17-05-31
Members of the board TitleAgeSince
Chief Executive Officer 66 22-01-26
Director/Board Member 77 17-09-30
Director/Board Member 61 17-05-31
More insiders
Date Price Change Volume
24-05-10 1,422 -4.50% 138,200
24-05-09 1,489 -0.87% 87,300
24-05-08 1,502 -1.64% 67,200
24-05-07 1,527 +1.06% 56,400
24-05-02 1,511 -2.33% 47,100

Delayed Quote Japan Exchange, May 10, 2024 at 02:00 am EDT

More quotes
CellSource Co., Ltd. is a Japan-based company engaged in regenerative medicine related business and consumer business. The Company operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW